Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TSYYJ
ADC Name
WO2024193682A1 32G1-8H10-CPT2
Synonyms
32G1-8H10-CPT2
   Click to Show/Hide
Organization
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Drug Status
Investigative
Antibody Name
undisclosed
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
CPT2
  Payload Info 
Therapeutic Target
DNA topoisomerase I (TOP1)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth lnhibition value (TGl) 
63.1
%
Patient-derived Xenograft B-NDG mice Model
Tumor Growth lnhibition value (TGl) 
80.4
%
Patient-derived Xenograft B-NDG mice Model
Tumor Growth lnhibition value (TGl) 
90.9
%
Patient-derived Xenograft B-NDG mice Model
Tumor Growth lnhibition value (TGl) 
91.5
%
Patient-derived Xenograft B-NDG mice Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
63.10%
Method Description
B-NDG mice were engrafted in the right flank with gastric cancer patient-derived tumortissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPBG-positive cells and MET-positive cells in the gastric tumor fragments were 10.1 1% and 1.19%, respectively, When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. The mice werethen injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 35.

   Click to Show/Hide
In Vivo Model Patient-derived Xenograft B-NDG mice Model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
80.40%
Method Description
B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 31.01% and 76.96%, respectively. When the tumors in the mice reached a volume of about 200-300mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.

   Click to Show/Hide
In Vivo Model Patient-derived Xenograft B-NDG mice Model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
90.90%
Method Description
B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 19.54% and 8.31%, respectively. When the tumors in the mice reached a volume of about 200-300 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 3mg/kg ADC's by i.v, BIW, administration. Determined tumor volume after the experiment, measured at day 32.

   Click to Show/Hide
In Vivo Model Patient-derived Xenograft B-NDG mice Model
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
91.50%
Method Description
B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.

   Click to Show/Hide
In Vivo Model Patient-derived Xenograft B-NDG mice Model
References
Ref 1 Anti-TPBG/MET antibodies and uses thereof